Personalis, Inc. provided earnings guidance for the full year of 2022. For the year, the company's total company revenue is expected to be in the range of $62.0 million to $67.0 million; Revenue from biopharma and all other customers, excluding the VA MVP, is expected to be in the range of $55.0 million to $60.0 million; and Net loss is expected to be in the range of $110.0 million to $115.0 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.43 USD | -5.92% | -8.63% | -31.90% |
May. 08 | Transcript : Personalis, Inc., Q1 2024 Earnings Call, May 08, 2024 | |
May. 08 | Earnings Flash (PSNL) PERSONALIS Reports Q1 Revenue $19.5M, vs. Street Est of $18.4M | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-31.90% | 73.23M | |
+29.77% | 49.46B | |
+1.00% | 42.58B | |
+49.56% | 42.49B | |
-5.26% | 29.09B | |
+13.68% | 26.61B | |
-22.99% | 18.64B | |
+8.22% | 13.16B | |
+32.41% | 12.55B | |
+24.01% | 12.1B |
- Stock Market
- Equities
- PSNL Stock
- News Personalis, Inc.
- Personalis, Inc. Provides Earnings Guidance for the Full Year of 2022